BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 29406053)

  • 1. Prostate Cancer Screening.
    Catalona WJ
    Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National evidence on the use of shared decision making in prostate-specific antigen screening.
    Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
    Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 7. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening: Actual trends on PSA marker. When, who, how?
    Baccaglini W; Cathelineau X; Araújo Glina FP; Medina LG; Sotelo R; Carneiro A; Sanchez-Salas R
    Arch Esp Urol; 2019 Mar; 72(2):98-103. PubMed ID: 30855010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in screening in 2015?
    Carlsson SV; Roobol MJ
    Curr Opin Urol; 2016 Sep; 26(5):447-58. PubMed ID: 27326657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
    Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
    Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making.
    Woods-Burnham L; Stiel L; Wilson C; Montgomery S; Durán AM; Ruckle HR; Thompson RA; De León M; Casiano CA
    Am J Mens Health; 2018 Jul; 12(4):751-759. PubMed ID: 29658371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
    Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
    BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
    Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
    Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    Gulati R; Psutka SP; Etzioni R
    J Urol; 2019 Nov; 202(5):936-943. PubMed ID: 31112106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Society of Behavior Medicine (SBM) Urges Congress to Ensure Affordable Care Act Coverage of Prostate Cancer Screening Support Services for High-Risk Men.
    Watson K; Buscemi J; Fitzgibbon M; Murray M; Murphy A; Abern M; Gann P; Levi JB; Stinson J; Diefenbach M; Winn RA
    Transl Behav Med; 2020 May; 10(2):492-494. PubMed ID: 30855080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.